» Articles » PMID: 37552779

How Low Can We (reliably) Go? A Method Comparison of Thyroid-stimulating Hormone Assays with a Focus on Low Concentrations

Overview
Journal Eur Thyroid J
Specialties Endocrinology
Oncology
Date 2023 Aug 8
PMID 37552779
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: International guidelines concerning subclinical hyperthyroidism and thyroid cancer advice absolute cut-off values for aiding clinical decisions in the low range of thyroid-stimulating hormone (TSH) concentrations. As TSH assays are known to be poorly standardized in the normal to high range, we performed a TSH assay method comparison focusing on the low range.

Methods: Sixty samples, selected to cover a wide range of TSH concentrations (<0.01 to 120 mIU/L) with oversampling in the lower range (<0.4 mIU/L), were used for the method comparison between three TSH immunoassays (Cobas, Alinity and Atellica). In addition, 20 samples were used to assess the coefficient of variation from duplicate measurements in these three methods.

Results: The TSH immunoassays showed standardization differences with a bias of 7-16% for the total range and 1-14% for the low range. This could lead to a different classification of 1.5% of all measured TSH concentrations <0.40 mIU/L measured in our laboratory over the last 6 months, regarding the clinically important cut-off value of TSH = 0.1 mIU/L. As the imprecision of the immunoassays varied from 1.6-5.5%, this could lead to a similar reclassification as the bias between immunoassays.

Conclusions: We established the standardization differences of frequently used TSH assays for the total and low concentration ranges. Based on the proportional bias and the imprecision, this effect seems to have limited clinical consequences for the low TSH concentration range. Nevertheless, as guidelines mention absolute TSH values to guide clinical decision-making, caution must be applied when interpreting values close to these cut-offs.

Citing Articles

A systematic review of subclinical hyperthyroidism guidelines: a remarkable range of recommendations.

Ursem S, Boelen A, Bruinstroop E, Elders P, Gussekloo J, Poortvliet R Eur Thyroid J. 2024; 13(3).

PMID: 38758966 PMC: 11227059. DOI: 10.1530/ETJ-24-0036.


Clinical Implications of Different Thyroid-Stimulating Hormone (TSH) Reference Intervals between TSH Kits for the Management of Subclinical Hypothyroidism.

Yoo W Endocrinol Metab (Seoul). 2024; 39(1):188-189.

PMID: 38311827 PMC: 10901656. DOI: 10.3803/EnM.2024.1934.

References
1.
Silva V, de Almeida R, Cavalcante M, Pereira Junior L, Reis F, Pereira M . Two Thyroid Stimulating Hormone assays correlated in clinical practice show disagreement in subclinical hypothyroidism patients. Clin Biochem. 2017; 53:13-18. DOI: 10.1016/j.clinbiochem.2017.12.005. View

2.
Kalaria T, Sanders A, Ford C, Buch H, Fenn J, Ashby H . Biochemical assessment of adequate levothyroxine replacement in primary hypothyroidism differs with different TSH assays: potential clinical implications. J Clin Pathol. 2021; 75(6):379-382. DOI: 10.1136/jclinpath-2020-207316. View

3.
Rawlins M, Roberts W . Performance characteristics of six third-generation assays for thyroid-stimulating hormone. Clin Chem. 2004; 50(12):2338-44. DOI: 10.1373/clinchem.2004.039156. View

4.
Kalaria T, Sanders A, Fenn J, Ashby H, Mohammed P, Buch H . The diagnosis and management of subclinical hypothyroidism is assay-dependent- Implications for clinical practice. Clin Endocrinol (Oxf). 2021; 94(6):1012-1016. DOI: 10.1111/cen.14423. View

5.
Clerico A, Ripoli A, Fortunato A, Alfano A, Carrozza C, Correale M . Harmonization protocols for TSH immunoassays: a multicenter study in Italy. Clin Chem Lab Med. 2017; 55(11):1722-1733. DOI: 10.1515/cclm-2016-0899. View